Sun Pharmaceutical Industries fell 1.98% to Rs 600.05 at 14:04 IST on BSE on reports the company is voluntarily recalling 2,528 bottles of its generic version of diabetes drug Glumetza from US-based Santarus Inc.
Meanwhile, the BSE Sensex was up 20.58 points, or 0.09%, to 21,940.37.
On BSE, so far 1.18 lakh shares were traded in the counter, compared with an average volume of 1.34 lakh shares in the past one quarter.
The stock hit a high of Rs 611 and a low of Rs 595.05 so far during the day. The stock hit a record high of Rs 653.10 on 3 March 2014. The stock hit a 52-week low of Rs 405.50 on 1 April 2013.
The stock had underperformed the market over the past one month till 7 March 2014, rising 1.80% compared with the Sensex's 7.57% rise. The scrip had, however, outperformed the market in past one quarter, rising 5.16% as against Sensex's 4.40% rise.
The large-cap company has an equity capital of Rs 207.12 crore. Face value per share is Re 1.
According to reports, Sun Pharmaceutical Industries began recalling the bottles of metformin HCL extended-release tables in the United States on 28 January 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin.
The company did not expect a significant impact by the recall, reports said.
The US Food and Drug Administration (USFDA) classified the recall as a "Class II," which signifies a remote chance of severe adverse consequences or death due to the product flaw, reports added.
Sun Pharma's consolidated net profit surged 73.73% to Rs 1531.09 crore on 51.59% increase in total income to Rs 4446.82 crore in Q3 December 2013 over Q3 December 2012.
Sun Pharmaceutical Industries is an international specialty pharmaceutical company with over 72% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
